Vor Biopharma Files 8-K for 'Other Events' on Jan 5, 2024

Ticker: VOR · Form: 8-K · Filed: Jan 5, 2024 · CIK: 1817229

Vor Biopharma Inc. 8-K Filing Summary
FieldDetail
CompanyVor Biopharma Inc. (VOR)
Form Type8-K
Filed DateJan 5, 2024
Risk Levelmedium
Pages1
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-governance, regulatory-filing, other-events

TL;DR

**Vor Biopharma filed an 8-K for 'Other Events' on Jan 5, 2024, watch for details.**

AI Summary

Vor Biopharma Inc. filed an 8-K on January 5, 2024, indicating an 'Other Events' disclosure. This filing, under SEC File Number 001-39979, simply reports an event that the company deems important enough to disclose, but does not fall under specific enumerated items. For investors, this means Vor Biopharma is transparently communicating an event, but without further details, its impact on the stock (VOR) is unclear, warranting close attention to subsequent disclosures.

Why It Matters

This filing signals that Vor Biopharma has an important, non-routine event to disclose, which could impact its operations or financial standing, and thus its stock price.

Risk Assessment

Risk Level: medium — The 'Other Events' classification means the specific nature and impact of the event are unknown, creating uncertainty for investors.

Analyst Insight

A smart investor would monitor Vor Biopharma's subsequent announcements and news releases closely for specific details about the 'Other Events' mentioned in this 8-K, as the nature of these events could significantly impact the company's valuation.

Key Players & Entities

  • Vor Biopharma Inc. (company) — the registrant filing the 8-K
  • January 5, 2024 (date) — date of earliest event reported and filing date
  • 001-39979 (other) — SEC File Number for Vor Biopharma Inc.
  • VOR (other) — trading symbol for Vor Biopharma Inc. on Nasdaq Global Select Market

Forward-Looking Statements

  • Vor Biopharma Inc. will release further details regarding the 'Other Events' disclosed in this 8-K. (Vor Biopharma Inc.) — high confidence, target: Q1 2024

FAQ

What is the purpose of an 8-K filing for 'Other Events'?

An 8-K filing for 'Other Events' (Item 8.01) is used by a company to disclose any material event that is not specifically covered by other items in Form 8-K but is still considered important enough to inform investors about, as stated in the filing's 'ITEM INFORMATION: Other Events'.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 5, 2024, as indicated by 'Date of Report (Date of earliest event reported): January 5, 2024'.

What is the trading symbol and exchange for Vor Biopharma Inc.?

Vor Biopharma Inc. trades under the symbol VOR on the Nasdaq Global Select Market, as listed under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the business address of Vor Biopharma Inc.?

The business address of Vor Biopharma Inc. is 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts, 02140, as detailed in the 'BUSINESS ADDRESS' section of the filing.

Is Vor Biopharma Inc. considered an emerging growth company?

The filing includes a checkbox 'Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions...' and then lists options, but does not explicitly check whether the registrant is an emerging growth company. The form asks to 'Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933', but no box is marked in the provided text.

Filing Stats: 418 words · 2 min read · ~1 pages · Grade level 11.6 · Accepted 2024-01-05 17:03:56

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob

Filing Documents

01

Item 8.01 Other Events On January 5, 2024, Vor Biopharma Inc. (the "Company") updated its investor presentation (the "Corporate Presentation"). The Corporate Presentation is available on the Company's website and is filed as Exhibit 99.1 hereto and incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits Exhibit No. Description 99.1 Corporate Presentation, dated January 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vor Biopharma Inc. By: /s/ Robert Ang Robert Ang Chief Executive Officer Date: January 5, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.